The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
Integrins in cancer: biological implications and therapeutic opportunities
Open accessAbstract
The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumours. The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. Integrin antagonists, including the αvβ3 and αvβ5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Self-citationPàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Self-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Integrin-regulated FAK–Src signaling in normal and cancer cells
Mitra, S. K., & Schlaepfer, D. D. (2006) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2006.08.011 · Cited by 1,590
Integrin signalling during tumour progression
Guo, W., & Giancotti, F. G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1490 · Cited by 1,471
Definition of Two Angiogenic Pathways by Distinct α v Integrins
Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., & Cheresh, D. A. (1995) · Science · doi:10.1126/science.270.5241.1500 · Cited by 1,321
Self-citationFrisch, S. M., & Screaton, R. A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00251-9 · Cited by 1,249
Pytela, R., Pierschbacher, M. D., & Ruoslahti, E. (1985) · Cell · doi:10.1016/0092-8674(85)90322-8 · Cited by 1,101
Cited by
Items 101–176 of 176
Sleeboom, J. J. F., van Tienderen, G. S., Schenke-Layland, K., van der Laan, L. J. W., Khalil, A. A., & Verstegen, M. M. A. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3840 · Cited by 375
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2953 · Cited by 374
Self-citationThe fast-growing field of photo-driven theranostics based on aggregation-induced emission
Zhang, Z., Kang, M., Tan, H., Song, N., Li, M., Xiao, P., Yan, D., Zhang, L., Wang, D., & Tang, B. Z. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01138c · Cited by 374
Keck, M. K., Zuo, Z., Khattri, A., Stricker, T. P., Brown, C. D., Imanguli, M., Rieke, D., Endhardt, K., Fang, P., Brägelmann, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2481 · Cited by 370
Hypoxia, inflammation, and the tumor microenvironment in metastatic disease
Finger, E. C., & Giaccia, A. J. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9224-5 · Cited by 370
Molecular functions of syndecan-1 in disease
Teng, Y. H.-F., Aquino, R. S., & Park, P. W. (2012) · Matrix Biology · doi:10.1016/j.matbio.2011.10.001 · Cited by 363
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.
Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352
Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment
Katsushima, K., Natsume, A., Ohka, F., Shinjo, K., Hatanaka, A., Ichimura, N., Sato, S., Takahashi, S., Kimura, H., Totoki, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13616 · Cited by 352
New medications for drug addiction hiding in glutamatergic neuroplasticity
Kalivas, P. W., & Volkow, N. D. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.46 · Cited by 349
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Itatani, Y., Kawada, K., Yamamoto, T., & Sakai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041232 · Cited by 346
Hu, K., Xie, L., Zhang, Y., Hanyu, M., Yang, Z., Nagatsu, K., Suzuki, H., Ouyang, J., Ji, X., Wei, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16513-0 · Cited by 346
Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy
Zamora, A., Vigueras, G., Rodríguez, V., Santana, M. D., & Ruiz, J. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.010 · Cited by 345
Xu, X. R., Zhang, D., Oswald, B. E., Carrim, N., Wang, X., Hou, Y., Zhang, Q., Lavalle, C., McKeown, T., Marshall, A. H., et al. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2016.1200008 · Cited by 338
Pathway-based personalized analysis of cancer
Drier, Y., Sheffer, M., & Domany, E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219651110 · Cited by 337
Drug resistance in metastatic castration-resistant prostate cancer
Seruga, B., Ocana, A., & Tannock, I. F. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.136 · Cited by 336
αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug
Graf, N., Bielenberg, D. R., Kolishetti, N., Muus, C., Banyard, J., Farokhzad, O. C., & Lippard, S. J. (2012) · ACS Nano · doi:10.1021/nn301148e · Cited by 327
Xu, X. R., Yousef, G. M., & Ni, H. (2018) · Blood · doi:10.1182/blood-2017-05-743187 · Cited by 325
v Integrins in Angiogenesis and Cancer
Weis, S. M., & Cheresh, D. A. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006478 · Cited by 311
Self-citationMesothelial Cells Promote Early Ovarian Cancer Metastasis through Fibronectin Secretion
Kenny, H. A., Chiang, C.-Y., White, E. A., Schryver, E. M., Habis, M., Romero, I. L., Ladanyi, A., Penicka, C. V., George, J., Matlin, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74778 · Cited by 303
A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis
Agrawal, P., Fontanals-Cirera, B., Sokolova, E., Jacob, S., Vaiana, C. A., Argibay, D., Davalos, V., McDermott, M., Nayak, S., Darvishian, F., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.007 · Cited by 303
The Use of Therapeutic Peptides to Target and to Kill Cancer Cells
J. Boohaker, R., W. Lee, M., Vishnubhotla, P., M. Perez, J. L., & R. Khaled, A. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712801661004 · Cited by 302
Najmeh, S., Cools-Lartigue, J., Rayes, R. F., Gowing, S., Vourtzoumis, P., Bourdeau, F., Giannias, B., Berube, J., Rousseau, S., Ferri, L. E., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30635 · Cited by 298
Integrin signalling adaptors: not only figurants in the cancer story
Cabodi, S., del Pilar Camacho-Leal, M., Di Stefano, P., & Defilippi, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2967 · Cited by 291
Zhu, P., Tan, M. J., Huang, R.-L., Tan, C. K., Chong, H. C., Pal, M., Lam, C. R. I., Boukamp, P., Pan, J. Y., Tan, S. H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.018 · Cited by 283
Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis
Läubli, H., & Borsig, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02120 · Cited by 282
Active targeting of gold nanoparticles as cancer therapeutics
Goddard, Z. R., Marín, M. J., Russell, D. A., & Searcey, M. (2020) · Chemical Society Reviews · doi:10.1039/d0cs01121e · Cited by 282
ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis
Dey, S., Sayers, C. M., Verginadis, I. I., Lehman, S. L., Cheng, Y., Cerniglia, G. J., Tuttle, S. W., Feldman, M. D., Zhang, P. J. L., Fuchs, S. Y., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78031 · Cited by 282
Huang, R.-L., Teo, Z., Chong, H. C., Zhu, P., Tan, M. J., Tan, C. K., Lam, C. R. I., Sng, M. K., Leong, D. T. W., Tan, S. M., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328716 · Cited by 281
Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides
Dissanayake, S., Denny, W. A., Gamage, S., & Sarojini, V. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.006 · Cited by 280
Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy
Li, J., Wang, Q., Xia, G., Adilijiang, N., Li, Y., Hou, Z., Fan, Z., & Li, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092233 · Cited by 278
Adhesion molecule signalling: not always a sticky business
Cavallaro, U., & Dejana, E. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3068 · Cited by 277
Design of Nanoparticle-Based Carriers for Targeted Drug Delivery
Yu, X., Trase, I., Ren, M., Duval, K., Guo, X., & Chen, Z. (2016) · Journal of Nanomaterials · doi:10.1155/2016/1087250 · Cited by 265
microRNA‐214 contributes to melanoma tumour progression through suppression of TFAP2C
Penna, E., Orso, F., Cimino, D., Tenaglia, E., Lembo, A., Quaglino, E., Poliseno, L., Haimovic, A., Osella‐Abate, S., De Pittà, C., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.102 · Cited by 261
The neurovascular link in health and disease: molecular mechanisms and therapeutic implications
Quaegebeur, A., Lange, C., & Carmeliet, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.013 · Cited by 247
Filopodia and adhesion in cancer cell motility
Arjonen, A., Kaukonen, R., & Ivaska, J. (2011) · Cell Adhesion & Migration · doi:10.4161/cam.5.5.17723 · Cited by 257
Targeted anticancer therapy: Overexpressed receptors and nanotechnology
Akhtar, M. J., Ahamed, M., Alhadlaq, H. A., Alrokayan, S. A., & Kumar, S. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.05.004 · Cited by 255
Cancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Yan, F., Wu, H., Liu, H., Deng, Z., Liu, H., Duan, W., Liu, X., & Zheng, H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.050 · Cited by 254
Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice
Li, L., Song, L., Liu, X., Yang, X., Li, X., He, T., Wang, N., Yang, S., Yu, C., Yin, T., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b04261 · Cited by 244
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Nanotechnology in Cancer Drug Delivery and Selective Targeting
Sutradhar, K. B., & Amin, M. L. (2014) · ISRN Nanotechnology · doi:10.1155/2014/939378 · Cited by 241
Schleich, N., Po, C., Jacobs, D., Ucakar, B., Gallez, B., Danhier, F., & Préat, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.059 · Cited by 238
Rizvi, I., Gurkan, U. A., Tasoglu, S., Alagic, N., Celli, J. P., Mensah, L. B., Mai, Z., Demirci, U., & Hasan, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216989110 · Cited by 234
Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway
Rapisarda, V., Borghesan, M., Miguela, V., Encheva, V., Snijders, A. P., Lujambio, A., & O’Loghlen, A. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.012 · Cited by 190
Quantitative Proteomics Identifies Proteins Enriched in Large and Small Extracellular Vesicles
Lischnig, A., Bergqvist, M., Ochiya, T., & Lässer, C. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100273 · Cited by 189
“gested to be associated with cancers (81, 82).”
Hota, P. K., & Buck, M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1019-0 · Cited by 170
Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150
Taubenberger, A. V., Bray, L. J., Haller, B., Shaposhnykov, A., Binner, M., Freudenberg, U., Guck, J., & Werner, C. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.03.017 · Cited by 139
iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery
Kang, S., Lee, S., & Park, S. (2020) · Polymers · doi:10.3390/polym12091906 · Cited by 139
Ultrasensitive tumour-penetrating nanosensors of protease activity
Kwon, E. J., Dudani, J. S., & Bhatia, S. N. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0054 · Cited by 131
Peptide Receptor Radionuclide Therapy: An Overview
Dash, A., Chakraborty, S., Pillai, M. R. A., & Knapp, F. F. (. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1741 · Cited by 128
Speicher, T., Siegenthaler, B., Bogorad, R. L., Ruppert, R., Petzold, T., Padrissa-Altes, S., Bachofner, M., Anderson, D. G., Koteliansky, V., Fässler, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4862 · Cited by 85
Devalliere, J., Chang, W. G., Andrejecsk, J. W., Abrahimi, P., Cheng, C. J., Jane‐wit, D., Saltzman, W. M., & Pober, J. S. (2014) · The FASEB Journal · doi:10.1096/fj.13-238527 · Cited by 83
Reardon, D. A., & Cheresh, D. (2011) · Genes & Cancer · doi:10.1177/1947601912450586 · Cited by 76
“These integrins play a significant role in tissue remodeling and angiogenesis and contribute to the growth and malignancy of a wide range of cancers.(7) Previous studies have revealed that α V integrin antagonists not only disrupt tumor angiogenesis but in some cases have a direct impact on the growth and malignant pr…”
BackgroundSelf-citationBeauvais, D. M., Jung, O., Yang, Y., Sanderson, R. D., & Rapraeger, A. C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0232 · Cited by 70
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Kim, K.-J., Kwon, S.-H., Yun, J.-H., Jeong, H.-S., Kim, H.-R., Lee, E. H., Ye, S.-K., & Cho, C.-H. (2017) · Oncogene · doi:10.1038/onc.2017.148 · Cited by 70
Lv, Y., Wang, H., Li, G., & Zhao, B. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.004 · Cited by 67
Tan, C., Wang, Y., & Fan, W. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5010201 · Cited by 63
“Another intensely studied class of tumor-targeting ligands is RGD-containing peptides, which recognize integrins, a family of receptor proteins that are overexpressed in angiogenic tumor endothelial cells, as well as a wide variety of solid tumors [40].”
BackgroundDorsch, M., Kowalczyk, M., Planque, M., Heilmann, G., Urban, S., Dujardin, P., Forster, J., Ueffing, K., Nothdurft, S., Oeck, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110056 · Cited by 55
Schlienger, S., Ramirez, R. A. M., & Claing, A. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2014.11.032 · Cited by 50
Matrikines for therapeutic and biomedical applications
Sivaraman, K., & Shanthi, C. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.056 · Cited by 50
Gasparri, A. M., Sacchi, A., Basso, V., Cortesi, F., Freschi, M., Rrapaj, E., Bellone, M., Casorati, G., Dellabona, P., Mondino, A., et al. (2019) · Small · doi:10.1002/smll.201903462 · Cited by 37
Lee, H. S., Oh, S. J., Lee, K.-H., Lee, Y.-S., Ko, E., Kim, K. E., Kim, H.-C., Kim, S., Song, P. H., Kim, Y.-I., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.572594 · Cited by 36
Bioactivity of thyroid hormone analogs at cancer cells
Davis, P. J., Tang, H.-Y., Hercbergs, A., Lin, H.-Y., Keating, K. A., & Mousa, S. A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00739 · Cited by 34
A new peptide ligand for colon cancer targeted delivery of micelles
Ren, Y., Mu, Y., Song, Y., Xie, J., Yu, H., Gao, S., Li, S., Peng, H., Zhou, Y., & Lu, W. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1077293 · Cited by 34
LncRNA NEAT1 Enhances Glioma Progression via Regulating the miR-128-3p/ITGA5 Axis
Chen, J., Wang, H., Wang, J., Niu, W., Deng, C., & Zhou, M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02474-y · Cited by 26
Brugarolas, J., Obara, G., Beckermann, K. E., Rini, B., Lam, E. T., Hamilton, J., Schluep, T., Yi, M., Wong, S., Mao, Z. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3029 · Cited by 25
Targeting tumor extracellular matrix with nanoparticles to circumvent therapeutic resistance
Ding, X., Liang, Y., Zhou, S., Wu, Y., Sałata, P., Mikolajczk-Martinez, A., Khosrawipour, V., & Zhang, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113786 · Cited by 20
You, T., Wang, Y., Li, K., Zhang, D., Wei, H., Luo, Y., Li, H., Lu, Y., Su, X., & Kuang, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.122 · Cited by 19
Tetrac as an anti-angiogenic agent in cancer
Schmohl, K. A., Nelson, P. J., & Spitzweg, C. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-19-0058 · Cited by 18
Osteopontin in Cancer: Mechanisms and Therapeutic Targets
Kariya, Y., & Kariya, Y. (2022) · International Journal of Translational Medicine · doi:10.3390/ijtm2030033 · Cited by 14
Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams
Serra, M., Rubes, D., Schinelli, S., & Paolillo, M. (2023) · Cancers · doi:10.3390/cancers15164173 · Cited by 13
Singh, D. P., Pathak, R., Chintalaramulu, N., Pandit, A., Kumar, A., Ebenezer, P. J., Kumar, S., Duplooy, A., White, M. E., Jambunathan, N., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00821-4 · Cited by 12
Iwatate, Y., Yokota, H., Hoshino, I., Ishige, F., Kuwayama, N., Itami, M., Mori, Y., Chiba, S., Arimitsu, H., Yanagibashi, H., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5350 · Cited by 11
Mayer, O., Wirsching, H., Schlingmann, S., Welzel, J., & Schuh, S. (2024) · Applied Sciences · doi:10.3390/app15010159 · Cited by 8
Metadata
- Authors
- Desgrosellier, J. S., & Cheresh, D. A.
- Venue
- Nature Reviews Cancer
- Published
- 2010-01
- Volume
- 10
- Issue
- 1
- Pages
- 9-22
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2147000598
- Cited by
- 3,736
- References
- 183
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.